CNMV
Markets Directorate General
C/ Edison núm. 4
28006 Madrid

Madrid, October 28, 2020

In accordance with article 227 of the recast Spanish Securities Market Act (*texto refundido de la Ley del Mercado de Valores*), approved by Royal Legislative Decree 4/2015, of 23 October, and related provisions, is hereby reported the following:

OTHER RELEVANT INFORMATION

Further to the Relevant Fact dated October 2, 2018 (registration number 270099) in relation to the communication of the submission by Pharma Mar, S.A. (the **"Company"**) of an action before the General Court of the European Union against the European Commission requesting the annulment of the Commission's Execution Decision C(2018)4831 final, by which the marketing authorization for the medicine plitidepsin was refused as a treatment for patients with multiple myeloma, the Company informs that the General Court of the European Union has notified today the judgment upheld in the aforementioned case.

The ruling (i) Annuls Commission Implementing Decision C(2018) 4831 final of 17 July 2018 refusing marketing authorisation under Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency, for Aplidin — plitidepsin, a medicinal product for human use; and (ii) Orders the Commission to pay the costs.

Please find attached press release that will be distributed to the media today.

Pharma Mar S.A.
Avda. de los Reyes, 1
P.I. La Mina
28770 Colmenar Viejo
(Madrid) Spain
www.pharmamar.com

The General Court of the European Union agrees with PharmaMar on the ruling on Aplidin® (plitidepsin)

- **The Court has granted in full, PharmaMar's application to annul the Commission's Enforcement Decision, which refused to authorize the marketing of plitidepsin as a Multiple Myeloma treatment.**
- **The Company asked the Court to clarify the procedural guarantees and examination criteria, the verification of conflicts of interest by the experts appointed by the EMA and the correct analysis of the scientific evidence.**
- **The ADMYRE Phase III registration study achieved its primary objective of Progression Free Survival (PFS).**
- **The last report from the *Rapporteur* and *Co-Rapporteur* was positive.**

Madrid, October 28th, 2020. – PharmaMar (MSE:PHM) announced today that the General Court of the European Union has granted PharmaMar's application, in full, annulling the European Commission's decision to refuse to market Aplidin® (plitidepsin) for the treatment of patients with multiple myeloma, ordering the Commission to pay the costs.

On October 1st, 2018, PharmaMar filed a lawsuit with the General Court of the European Union against the European Commission, requesting the annulment of the Commission Implementing Decision, which refused to authorize the marketing of plitidepsin as a treatment for patients with multiple myeloma.

In this application, the Company requested the Court to clarify the procedural guarantees and examination criteria to be applied during a marketing authorization procedure before the European Medicines Agency (EMA). Specifically, the main grounds of the lawsuit related to the strict verification of conflicts of interest by the experts appointed by the EMA and the correct analysis of the scientific evidence presented by PharmaMar.

Today's decision by the European General Court confirms PharmaMar's long-standing position on the evaluation process of plitidepsin as a treatment for patients with multiple myeloma.

Legal warning

This press release does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.

About PharmaMar

Headquartered in Madrid, PharmaMar is a biopharmaceutical company, focused on oncology and committed to research and development which takes its inspiration from the sea to discover molecules with antitumor activity. It is a company that seeks innovative products to provide healthcare professionals with new tools to treat cancer. Its commitment to patients and to research has made it one of the world leaders in the discovery of antitumor drugs of marine origin.

PharmaMar has a pipeline of drug candidates and a robust R&D oncology program. It develops and commercializes Yondelis® in Europe and has other clinical-stage programs under development for several types of solid cancers: Zepzelca™ (lurbinectedin, PM1183), PM184 and PM14. With subsidiaries in Germany, Italy, France, Switzerland, Belgium, Austria and the United States. PharmaMar wholly owns other companies: GENOMICA, a molecular diagnostics company; Sylentis, dedicated to researching therapeutic applications of gene silencing (RNAi). To learn more about PharmaMar, please visit us at www.pharmamar.com.

Media Contact:

Alfonso Ortín – Communications Director aortin@pharmamar.com Mobile: +34 609493127
Miguel Martínez-Cava – Communication Manager mmartinez-cava@pharmamar.com Mobile: +34 606597464
Álvaro Mateo - Communication Manager amateo@pharmamar.com Mobile: +34 650726009

Phone: +34 918466000

Capital Markets & Investor Relations:

José Luis Moreno– Capital Markets & Investor Relations Director
María Marín de la Plaza – Capital Markets & Investor Relations
investorrelations@pharmamar.com
Phone: +34 914444500

Or please visit our website at www.pharmamar.com